Saniona satser på spinout-virksomheder

Scandion Oncology A/S and Solural Pharma ApS have entered into an agreement regarding manufacturing of SCO-101 tablets for clinical phase II trials with drug-resistant cancer patients. Scandion Oncology will soon be completing the validation and substance production of SCO-101 at Cambrex, Sweden. Next step will be to initiate production of tablets. Scandion Oncology has employed an experienced team of drug production specialists. The team has previously been involved in the original production and formulation of SCO-101 in the four completed phase I studies. Saniona, the main shareholder in Scandion Oncology, recently performed a legally required audit of Solural Pharma. This audit is valid and usable for Scandion Oncology. The manufacturing of SCO-101 tablets is in accordance with Scandion Oncology’s plans and targets for 2019.

Scandion Oncology A/S (Scandion Oncology) hereby announces that Scandion Oncology, together with University of Copenhagen, has discovered that a number of Scandion Oncology’s compounds are able to overcome antibiotic resistance in bacterial infections through a new mechanism of action. These are findings from preclinical studies. The discovery may pave the way for new drugs for treatment of antibiotic resistance. Scandion Oncology has filed a patent application and owns all rights to this invention. Scandion Oncology is currently exploring the commercial opportunities for these novel findings, since the market for these types of drugs is significant. The outcome of the exploration of the commercial opportunities will weigh in on Scandion Oncology’s decision on how the indication should be further advanced. Scandion Oncology continues to have a strict focus on drug resistance in oncology, but sees this new discovery as a very interesting complement to the Scandion Oncology portfolio. Presently, the Scandion Oncology efforts within antibiotic resistance only requires small-scale resources.

Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes the year-end report for the period January - December 2018. The year-end report is available on the Company"s website (www.scandiononcology.com). Below is a summary of the report.

Scandion Oncology A/S ("Scandion Oncology") today announces that the Chairman of the Board Jørgen Bardenfleth and Board member Carl Borrebaeck acquire shares from CEO Nils Brünner and CSO Jan Stenvang. Moreover, Nils Brünner and Jan Stenvang acquire shares from former CEO Kim Arvid Nielsen. Below is a description of the transactions. All transactions are done outside the market.

Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has selected Radboud University Medical Centre in Nijmegen, the Netherlands, as collaborator for the Boost4Health internationalisation voucher. As previously announced this grant amounts to EUR 14,999. Scandion Oncology received additionally EUR 5,000 from the Boost4Healths program (Product Validation voucher). The scientific collaboration concerns the use of SCO-101 to revert resistance to anti-estrogen treatment in patients with advanced breast cancer.

Scandion Oncology A/S (”Scandion Oncology”) herby reports interim report for Q3 2018.

Scandion Oncology A/S has been granted an Impact Voucher of 14.999 EUR from Biopeople, Denmark’s Life Science Cluster, as partner in the Boost4Health Interreg project of leading bioregions in North-West Europe. The Impact Voucher supports SCO-101 development in relation to anti-estrogen resistance in breast cancer. The selection committee of Boost4Health based their decision on the benefit of providing access to European partners and markets and to the advancement of product validation for Scandion Oncology A/S.

Today, November 8, 2018, is the first day of trading in Scandion Oncology A/S’s (“Scandion Oncology”) shares on Spotlight Stock Market. The share is traded under the ticker SCOL and ISIN code DK0061031895.

Första handelsdag på Spotlight Stock Market för Scandion Oncology A/S aktie är den 8 november 2018. Kortnamnet för aktien är SCOL.

On October 18, 2018, the subscription period for Scandion Oncology A/S’s ("Scandion Oncology") new share issue of approx. SEK 26 million prior to listing on Spotlight Stock Market (“Spotlight”) was completed. Scandion Oncology received subscription for a total of approx. SEK 104.7 million, including presubscription commitments, from a total of 74 pre-subscribers. This corresponds to a total subscription ratio of approx. 402.7 percent. Through the new share issue, Scandion Oncology will receive approx. 1 500 new shareholders. Settlement notes are scheduled to be sent to all allotted shareholders today.

Today, October 4, 2018, the subscription period for Scandion Oncology A/S ("Scandion Oncology") new share issue begins, prior to planned listing on Spotlight Stock Market. The subscription period expires on October 18, 2018. With a fully subscribed new share issue, the company will receive a maximum of approximately SEK 26 million before issue costs. The company has secured pre-subscriptions of approximately SEK 18.5 million, corresponding to approximately 71 percent of the planned issue amount. Memorandum, teaser and subscription forms are available through the websites of Scandion Oncology (www.scandiononcology.com) and Sedermera Fondkommission (www.sedermera.se). The investment documents are also available via Spotlight’s website (www.spotlightstockmarket.com). Subscription of shares can be made by submitting a subscription form to Sedermera Fondkommission or through their website (via BankID) or Nordnet Bank (www.nordnet.se). For subscription of shares directly through other banks, the subscriber is asked to contact his or her bank.

Idag, den 4 oktober 2018, inleds teckningstiden i Scandion Oncology A/S ("Scandion Oncology") nyemission inför planerad notering på Spotlight Stock Market (”Spotlight”). Teckningstiden löper till och med den 18 oktober 2018. Vid fulltecknad nyemission tillförs bolaget högst cirka 26 MSEK före emissionskostnader. Bolaget har på förhand via teckningsförbindelser skriftligen avtalat om cirka 18,5 MSEK, motsvarande cirka 71 procent av emissionsvolymen. Memorandum, teaser och anmälningssedel finns tillgängliga på Scandion Oncologys (www.scandiononcology.com) och Sedermera Fondkommissions (www.sedermera.se). Investeringsdokumenten finns även tillgängliga via Spotlights hemsida (www.spotlightstockmarket.com). Teckning av aktier kan göras genom insändande av anmälningssedel till Sedermera Fondkommission eller via Sedermeras hemsida (genom BankID) alternativt Nordnet Bank (www.nordnet.se). För teckning av aktier direkt genom övriga banker ombedes tecknaren att kontakta sin bank.

Today, Scandion Oncology A/S (“Scandion Oncology”) announces that the company has been approved for listing at Spotlight Stock Market (”Spotlight”). The approval is given under the condition that the company raises the minimum limit and that the company obtains a sufficient number of shareholders in accordance with Spotlight’s listing agreement in the upcoming IPO. The company plans to raise approximately 26 MSEK and the subscription period will run from October 4, 2018, to October 18, 2018, both dates inclusive. The company has secured pre-subscription of 18.5 MSEK, corresponding to approximately 71 percent of the planned issue amount.

Scandion Oncology A/S (“Scandion Oncology”) meddelar idag, den 1 oktober 2018, att bolaget har godkänts för notering på Spotlight Stock Market (“Spotlight”) förutsatt att lägsta gränsen i bolagets kommande nyemission uppnås samt att marknadsplatsens ägarspridningskrav uppnås. Bolaget meddelar även att teckningstiden för nyemissionen om cirka 26 MSEK inleds den 4 oktober 2018 och pågår till och med den 18 oktober 2018. Bolaget har på förhand via teckningsförbindelser skriftligen avtalat om 18,5 MSEK, motsvarande cirka 71 procent av emissionsvolymen.